- Parties: The plaintiff was Salix Pharmaceuticals, Inc. The defendant was Sandoz Canada Inc.

- Subject Matter: This Federal Court action was commenced pursuant to subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations, involving a patent infringement claim by Salix Pharmaceuticals, Inc. against Sandoz Canada Inc. concerning Canadian Patent No. 2,739,436, which relates to the use of rifaximin for the treatment and prevention of hepatic encephalopathy (the branded product being ZAXINE). Sandoz filed an Abbreviated New Drug Submission for a proposed generic rifaximin product and served a Notice of Allegation dated January 14, 2025, alleging non-infringement and invalidity of the patent; Sandoz has also filed a counterclaim seeking declarations that the 436 Patent is invalid and has not been infringed. The case is ongoing.

- Date: The hearing was set on April 01, 2026.

- Venue: This was a federal case before the Federal Court.

- Amount: No financial award was specified.